Trial Profile
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Glofitamab (Primary) ; Obinutuzumab (Primary) ; Tocilizumab (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms STARGLO
- Sponsors Roche
- 15 Apr 2024 Results from this trial presented in a Roche's media release.
- 15 Apr 2024 Results published in the Genentech Media Release.
- 15 Apr 2024 According to a Roche media release, the company to present data from this trial at an upcoming medical meeting and will be shared with health authorities.